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1. Introduction  
Cytomegalovirus (CMV) infection is a major cause of morbidity in kidney transplant 
recipients. CMV seropositivity is common in the general population, with a reported 
prevalence ranging from 30 to 97% (Paya, 2001; Preiksaitis et al., 2005). After primary 
infection, CMV establishes life-long latency. During the past 2 decades, major advances in 
the management of CMV infection of transplant patients have been achieved with new 
diagnostic techniques and the use of antiviral agents.  
Most transplant centers have protocols for the diagnosis and monitoring of CMV, while 
strategies for the treatment of clinically significant infections as well as prophylactic and 
preemptive therapy have become common practice. Such strategies address both clinically 
significant disease and the indirect effects of CMV infection, increased risk of allograft 
rejection and other infections. 
Several guidelines been published within the last few years regarding the management of 
CMV in transplant patients, diagnostic procedures, and prevention by prophylaxis or 
preemptive therapy.   
The following definitions are commonly used in the transplant literature and are consistent 
with the American Society of Transplantation (AST) and The Transplantation Society (TTS) 
recommendations for use in clinical trials (Humar & Michaels, 2006; Kotton et al., 2010): 
 CMV infection: evidence of CMV replication regardless of symptoms 
 CMV disease: evidence of CMV infection with attributable symptoms. CMV disease can 
be further categorized as either a viral syndrome with fever and/or malaise, 
leucopenia, and thrombocytopenia, or as tissue-invasive disease (e.g., pneumonitis, 
hepatitis, retinitis, and gastrointestinal disease). 
A number of review articles on CMV-associated problems in kidney transplantation can aid 
the clinician working with these patients. These reviews include information on its clinical 
signs and symptoms, indirect effects, diagnosis, prevention, and treatment protocols. 
However, the manifestations of CMV infection vary among patients, in part depending on 
their CMV serostatus. In fact, the prevalence, clinical manifestations, and effects of CMV 
depend on the patient’s serostatus. In this overview, we summarize the current status of 
CMV, focusing primarily on adult kidney transplant patients who are CMV donor 
positive/recipient positive (CMV D+/R+). 
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2. Epidemiology and pathogenesis 
CMV is a widespread pathogen that causes an asymptomatic or mild mononucleosis-like 
primary infection, which usually occurs in early childhood or adolescence. The prevalence 
of CMV seropositivity ranges from 40 to 100% worldwide, with lower rates in Europe, parts 
of North America, and Australia, and higher rates in Africa and Asia (Ho, 1990). In regions 
with higher rates of CMV seropositivity, rates of CMV disease after kidney transplantation 
may be lower, as populations with immunity to CMV are less likely to have active disease 
(Kanter et al., 2009). 
Like other herpes viruses, CMV can establish latency. After primary infection, the virus may 
persist at specific sites in the host without any detectable viral infection (Sinclair & Sissons, 
2006). Sporadic reactivation events may occur, but they are generally controlled by cell-
mediated immunity, cytotoxic T-cells, and NK cells. Blood leukocytes, and mononuclear 
cells in particular, are generally the sites of latency, but viral DNA has been detected in bone 
marrow hematopoietic progenitors, epithelial cells, and endothelial cells.  
The latent virus can thus be easily transmitted from a transplant donor to recipient by either 
the leukocytes, or possibly even tissue cells, of the kidney. Transplant patients’ cell-
mediated immunity is impaired and cannot control the virus, resulting in reactivation of the 
donor virus in CMV-seronegative recipients without immunity to CMV (D+/R-), as well as 
in CMV-seropositive (R+). Other recipients undergo reactivation of their own latent virus. 
CMV is thought to be a risk factor for other viral infections, as well as invasive fungal and 
bacterial infections in transplant recipients (Fishman & Rubin, 1998). 
 Without prophylaxis, CMV infections occur in the majority of kidney transplant patients, 
primarily during the first 3 months, when immunosuppression is most powerful. The risk 
factors for CMV disease in transplant recipients include CMV seropositive donor/CMV 
seronegative recipient (D+/R-) and the intensity of immunosuppressive therapy. It has been 
reported that CMV donor positive/recipient positive status was not a risk factor for CMV 
replication or disease in kidney transplant recipients (Bataille et al., 2010). 
3. Clinical impact of CMV infection 
3.1 Direct effects 
Symptoms of CMV disease are largely nonspecific, such as fever, fatigue, body aches, and 
myelosuppression. In some patients, CMV disease is manifested as tissue-invasive disease. 
The gastrointestinal tract is the most common site for tissue-invasive CMV disease, 
independent of the type of allograft transplant (Faure-Della Corte et al., 2010), which can 
cause abdominal pain and diarrhea. In severe cases, CMV ulceration of the gastrointestinal 
tract can lead to hemorrhage and perforation. Other organs that may manifest tissue-
invasive disease include the liver, lungs, heart, pancreas, and kidneys, and may present with 
allograft dysfunction easily misdiagnosed as acute or chronic rejection (Couzi et al., 2010). 
3.2 Indirect effects 
CMV is associated with a variety of indirect effects due to the virus’ ability to modulate the 
immune system (Couzi et al., 2010). Kidney transplant recipients with CMV infection or 
disease are more likely to develop opportunistic infections from other viruses (e.g., human 
herpesvirus [HHV]-6, HHV-7, and Epstein-Barr virus-related post-transplant 
lymphoprohferative disease) (Razonable & Paya, 2003; Razonable et al., 2003), bacteria (e.g., 
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Nocardia spp.) (Peleg et al., 2007), and fungi (Husni et al., 1998). In addition to infections, 
patients with CMV infection are more likely to experience acute and chronic rejection.  
CMV infection has also been described as an independent risk factor for atherosclerosis in 
kidney transplant recipients (Hodson et al., 2005). In addition, new-onset diabetes mellitus 
has been reported in patients with CMV infection or disease after kidney transplantation 
(Hartmann et al., 2006; Rodrigo et al., 2006). Research has shown that the development of ┛-
├ T cells in response to CMV is associated with a lower risk of malignancy after kidney 
transplantation (Couzi et al., 2010). CMV infection is associated with a higher rate of 
allograft failure and death in kidney transplant recipients, in part due to increased 
opportunistic infections as well as acute and chronic allograft rejection (Razonable & Paya, 
2003; Sagedal et al., 2007). In one study, CMV persistence in the allograft was associated 
with reduced allograft function and survival after kidney transplantation (Helantera et al., 
2006). In regard to treatment, primary antiviral prophylaxis appears to be more effective in 
preventing the indirect effects of CMV than pre-emptive therapy (Hodson et al., 2005; Kalil 
et al., 2005). 
4. Diagnosis 
The diagnosis of CMV infection and disease has evolved considerably. Historically, the 
diagnosis of CMV disease was made by histopathology, which requires an invasive 
procedure to obtain samples. Serologic assays appear to have limited clinical utility after 
transplantation, and should not be used to diagnose acute disease in kidney transplant 
recipients (Humar et al., 2005). 
For years, culture-based methods (tissue culture and shell vial centrifugation culture) were 
used for CMV diagnosis. Tissue cultures can take weeks, however, and the shell vial 
centrifugation assay is less sensitive than molecular assays (Mazzulli et al., 1999). 
Nonetheless, tissue cultures are useful to grow CMV isolates in the laboratory for 
phenotypic antiviral resistance testing, although the latter technique has been replaced 
predominantly by genotypic resistance testing.  
The pp65 antigenemia assay is a semi-quantitative fluorescent assay based on detection of 
infected cells in the peripheral blood. This assay has far higher sensitivity and specificity 
than culture-based methods (Mazzulli et al., 1999), and is comparable in sensitivity to CMV 
PCR (Caliendo et al., 2000). Though not fully quantitative, it can provide an estimate of the 
magnitude of viral load from the number of infected cells. Molecular diagnostic tests detect 
DNA or RNA, are qualitative and quantitative, and the majority are highly sensitive for 
CMV.  
Quantitative measurement of CMV-DNA levels has become popular at many centers. 
Commonly used assays include PCR testing of plasma or whole blood, which is 
commercially available. Whole blood assays often have higher viral loads than plasma 
assays. In general, the highest viral loads are associated with tissue-invasive disease, while 
the lowest are seen with asymptomatic CMV infection (Kim et al., 2011). In addition to the 
absolute value of viral load, the rate of rise is also an important factor (Emery et al., 2000). Of 
note, it is possible for patients with tissue invasive disease (especially gastrointestinal or 
retinal disease) to occasionally have undetectable blood viral loads.  
Both the pp65 antigenemia assay and quantitative CMV viral load testing can be utilized in 
preemptive protocols, to diagnose of CMV disease, and to guide management (Caliendo et 
al., 2000; Emery et al., 2000; Kim et al., 2011). A major problem of these assays is the lack of 
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standardization. A recent multicenter comparison of viral load assays demonstrated up to a 
1000 folds variation among them. Standardization may be achieved in the future with 
quantitative viral load assays (Pang et al., 2003).  
5. Antiviral prophylaxis and preemptive therapy 
There are very few randomized trials comparing preemptive therapy with prophylaxis in 
the prevention of CMV in kidney transplant recipients with CMV D+/R+ status. Reasons for 
this include variation among transplant programs, different end-point definitions, non-
standardized testing methodologies, and different patient populations. 
Two strategies are commonly used for CMV prevention: antiviral prophylaxis and 
preemptive therapy. Antiviral prophylaxis involves giving antiviral therapy to all ‘at-risk’ 
patients (or a specified subset) beginning in the early post transplant period for a defined 
duration, such as 3 to 6 months. In preemptive therapy, patients are monitored regularly by 
laboratory assay (often weekly) for early evidence of CMV replication. Patients with 
detectable replication are then treated with antiviral therapy to prevent symptomatic 
disease.  
Each approach has advantages and disadvantages that must be considered in the context of 
the patient and the allograft (Table 1) (Fishman et al., 2007; Torres-Madriz & Boucher, 2008). 
Preemptive therapy may decrease drug costs and toxicity, but requires excellent logistic 
coordination in order to obtain, receive, and act on results in a timely fashion, which can be 
difficult if patients live far from the transplant center. In addition, due to a lack of 
standardized diagnostic testing, optimal threshold values for the initiation of preemptive 
therapy have not been defined. Antiviral prophylaxis has the theoretical advantage of 
preventing reactivation of other viruses such as HHV-6 and may thus be more likely to 
prevent the indirect effects of CMV. Meta-analyses have demonstrated that antiviral 
prophylaxis is associated with decreased graft loss, decreased opportunistic infections, and 
improved survival (Kalil et al., 2005; Small et al., 2006). Late-onset CMV disease is a 
potential limitation of prophylaxis. 
 
 Prophylaxis Preemptive therapy 
Efficacy Yes Yes 
Ease Relatively ease to coordinate More difficult to coordinate 
Test thresholds not  
Standardized 
Late onset disease A potential problems Much less commonly seen 
Cost Higher drug costs Higher laboratory costs 
Toxicity Potential for greater toxicity 
(myelosuppression) 
Potential for less drug toxicity 
with shorter courses of 
antivirals 
Indirect effects 
(e.g. graft loss, 
mortality, and 
opportunistic infections) 
Consistent and positive impact 
based on meta-analyses and 
limited comparative trials 
Very limited data that 
preemptive therapy affects 
indirect effects 
Table 1. Prophylaxis versus preemptive therapy. 
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5.1 Antiviral prophylaxis 
Drugs that have been evaluated for antiviral prophylaxis include ganciclovir, valganciclovir, 
acyclovir, valacyclovir, and immune globulin preparations (Table 2). All doses should be 
adjusted based on renal function. Ganciclovir is available in both oral and intravenous 
formulations. The literature contains several large, multicenter, randomized trials of 
prophylaxis with oral ganciclovir, valganciclovir, and valacyclovir (Hodson et al., 2008). 
Valganciclovir is a valine ester pro-drug of ganciclovir with better bioavailability (50–60%) 
than oral ganciclovir (6–9%) (Perrottet et al., 2009). 
Acyclovir has less activity against CMV and is not recommended specifically for 
prophylaxis. The efficacy of prophylaxis with either CMV immune globulin (CMVIG) or 
intravenous immune globulin (IVIG) in kidney organ transplant recipients has been 
investigated in relatively few trials (Hodson et al., 2007), the majority of which have been 
randomized, but not blinded. Further research is needed to delineate the benefit of adding 
immune globulin to current CMV prophylaxis regimens. 
 
Drug 
Usual adult prophylaxis 
dose 
Comments on use and major toxicity 
Valganciclovir 900mg once daily Ease on administration; leukopenia 
Oral ganciclovir 1g three times daily Low oral bioavailablility: high pill 
burden 
IV ganciclovir 5mg/kg once daily Intravenous access; leucopenia 
Valacyclovir 2g four times daily High pill burden; neurological effects 
Table 2. Currently available drugs for CMV prophylaxis. 
5.1.1 Late onset CMV disease 
The major problem with CMV prophylaxis continues to be late-onset CMV disease, defined 
as disease occurring after discontinuation of antiviral prophylaxis. For 3-month prophylaxis 
regimens, this typically occurs between 3 and 6 months post transplant, but occasionally 
occurs later. Late onset CMV disease can be difficult to diagnose, especially in patients who 
live far away from their primary transplant program. Late onset CMV disease contributes to 
morbidity and has been associated with higher overall mortality (Limaye et al., 2004).  
Potential options for dealing with late-onset CMV disease are as follows: (1) careful clinical 
follow-up with treatment as soon as symptoms occur, and (2) virologic monitoring after 
completion of prophylaxis, such as periodic measurement of antigenemia or viral load for 8 
to 12 weeks. However, studies evaluating the utility of post-prophylaxis monitoring have 
demonstrated poor sensitivity and specificity in predicting CMV disease (Humar et al., 
2004). Weekly monitoring may be required to increase sensitivity.   
5.2 Preemptive therapy 
Preemptive therapy involves monitoring for early evidence of CMV replication followed by 
early treatment to prevent symptomatic disease (Paya, 2001; Preiksaitis et al., 2005). 
Preemptive therapy has the potential advantage of targeting patients at higher risk, thereby 
decreasing drug costs and toxicity. A sound preemptive strategy includes careful selection 
of the patient, the optimal laboratory test, the duration of monitoring, and the type, dose, 
and duration of an antiviral agent. 
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The best laboratory test to monitor is either a viral load test or a pp65 antigenemia assay. 
Site-specific and assay-specific threshold values for initiation of preemptive therapy should 
be locally validated prior to institution of a preemptive protocol. The optimal monitoring 
strategy is approximately once weekly testing for 12 weeks post transplant.  
Once viremia is detected, treatment should be initiated with either oral valganciclovir (900 
mg twice a day) or intravenous ganciclovir (5 mg/kg twice a day). Therapy should be 
continued until viremia is undetectable. A randomized trial found that these agents had 
equal efficacy for treatment of mild to moderate CMV disease (Asberg et al., 2007). As the 
aim of preemptive therapy is to treat low-level asymptomatic viremia, oral valganciclovir is 
preferable to intravenous ganciclovir for logistical issues. Further studies are required to 
determine comparative efficacy of preemptive therapy versus prophylaxis, especially 
regarding the indirect sequelae of CMV. 
5.3 Comparison of antiviral prophylaxis and preemptive therapy 
Only relatively small trials have compared universal prophylaxis with preemptive therapy. 
In a study comparing oral ganciclovir prophylaxis with preemptive intravenous ganciclovir 
in kidney transplant patients, prophylaxis reduced the incidence of CMV infection over 12 
months by 65% (13/73 versus 33/65 patients) and improved 4-year graft survival (Kliem et 
al., 2008). A trial of 98 kidney transplant patients randomly assigned to preemptive therapy 
or prophylaxis with valganciclovir for 100 days showed that both strategies were effective in 
preventing symptomatic CMV infection (Khoury et al., 2006). Another study that compared 
preemptive therapy with universal prophylaxis found significantly higher rates of biopsy-
proven acute rejection in the preemptive therapy group (Reischig et al., 2008).  
Recently, 2 studies reported directly opposed results in CMV-seropositive kidney transplant 
recipients receiving antiviral prophylaxis or preemptive treatment with valganciclovir. One 
study found no difference between groups in the incidence of CMV syndrome (4% vs. 5%; 
P=0.67), CMV disease (0% vs. 2%; P=0.45), or acute rejection (10% vs. 5%, P=1.00) 
(McGillicuddy et al., 2010). The other study found that CMV reactivation 1 year post-
transplant in 67.4% and 28% of preemptive and prophylactic groups, respectively (P<0.001). 
In addition, the study found a significantly greater incidence of CMV disease in the 
preemptive group than in the prophylactic group (9.8% vs. 2.68%, P=0.021) (Weclawiak et 
al., 2010). Several meta-analyses found that although preemptive therapy was effective in 
reducing the relative risk of CMV, all-cause mortality was not altered (Hodson et al., 2005; 
Kalil et al., 2005; Small et al., 2006). 
Guidelines regarding prophylaxis management favor the use of prophylaxis over preemptive 
therapy in intermediate-risk, CMV-seropositive transplant recipients, based on the available 
data suggesting better graft survival and clinical outcomes.(Humar & Michaels, 2006; Kotton 
et al., 2010) Individual transplant centers must weigh the risks and benefits of each approach, 
based on the frequency of CMV disease in their center, their ability to monitor recipients, cost 
of antiviral medications and diagnostics, local rates of late onset CMV disease, and the 
incidence of other opportunistic infections, graft loss, rejection, and mortality. 
6. Treatment of established CMV disease 
Intravenous ganciclovir has been used to successfully treat CMV disease in kidney 
transplant recipients in over 30 uncontrolled, non-randomized, therapeutic trials (Preiksaitis 
et al., 2005) and is has been considered the mainstay of therapy. The typical dose of 
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intravenous ganciclovir is 5 mg/kg twice daily. The duration of therapy in trials varied from 
2 to 4 weeks. Valganciclovir at a dose of 900 mg twice daily achieves levels similar to 
intravenous ganciclovir treatment. In a randomized controlled trial comparing 3 weeks of 
oral valganciclovir to intravenous ganciclovir for the treatment of mild to moderate CMV 
disease in 321 organ transplant patients, the vast majority of whom were kidney transplant 
recipients, both drugs had similar efficacy for the eradication of viremia 21 days post-
treatment (Asberg et al., 2007). However, in the per-protocol population, a significant 
number of patients had persistent viremia at day 21, suggesting that longer courses of 
therapy are appropriate in some patients.  
CMV disease should be treated for at least 2 weeks or until the following criteria are met: 
clinical resolution of symptoms and virologic clearance below a threshold negative value.  
Intravenous ganciclovir is preferable to oral valganciclovir in patients with severe or life-
threatening disease, or in patients with impaired gastrointestinal absorption (e.g., significant 
diarrhea). Acyclovir and oral ganciclovir are not effective in treating CMV disease in 
transplant recipients. While oral ganciclovir has been shown to prevent CMV disease, it is 
not recommended as a treatment due to concerns about emergence of ganciclovir-resistant 
CMV strains in the presence of CMV replication. 
It is unclear whether addition of IVIG or CMVIG to existing treatment regimens has a 
benefit for solid organ transplant recipients, but it can be considered for patients with CMV 
pneumonitis or other severe disease. 
Overall, molecular diagnostic tests can be used to tailor the duration of antiviral therapy 
based on clearance of CMV viral load or antigenemia. This risk of relapse is lower in 
patients who have no detectable CMV viral load at the end of therapy than for those with a 
detectable CMV viral load (Asberg et al., 2009; Humar et al., 2002). Therefore, patients with 
evidence of CMV viremia should be maintained on therapy until viremia (measured either 
by antigenemia or nucleic acid testing) has dropped below the negative threshold value for 
a given test, a value that remains poorly defined in ultra-sensitive assays. After completion 
of treatment, a 1 to 3 month course of secondary prophylaxis may be considered depending 
on the clinical situation. An alternative option is close clinical and/or virologic follow-up 
after discontinuation of treatment.  
7. Conclusion 
Although, new therapeutic procedures and the use of modern diagnostic methods have 
reduced the incidence of severe infections, CMV remains a common disease that negatively 
influences kidney transplant outcomes. In addition to viral factors and pharmacological 
immunosuppression, the roles of innate and adaptive immune deficiencies are now being 
recognized in its pathogenesis.    
Prevention of CMV with antiviral prophylaxis and preemptive therapy are both effective, 
but have distinct disadvantages. The direct and indirect effects of CMV may be reduced by 
prophylaxis with antiviral agents, though late onset primary infections may complicate the 
post-transplant course. Furthermore, many CMV-seropositive recipients who will never 
develop CMV reactivation are exposed to drugs during prophylaxis. On the other hand, 
preemptive therapy is based on the frequent laboratory monitoring of viral load, and some 
patients develop a symptomatic infection before the diagnosis of CMV viremia.  
Large randomized clinical trials are needed to establish a casual relationship between CMV 
reactivation and graft injury. In particular, they should analyze long-term graft survival and 
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compare prophylaxis with preemptive therapy in D+/R+, with particular attention to 
patients receiving preemptive therapy who have no episodes of positive antigenemia and 
therefore are not receiving anti-CMV treatments. 
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